Trial Profile
Single arm, open, prospective study low dose of Apatinib in the treatment of primary and recurrent high grade gliomas
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Temozolomide
- Indications Glioma
- Focus Therapeutic Use
- 23 Apr 2018 New trial record